From the CEO
Analysis Group Forum: Summer 2013
More than 80% of best-selling drugs have been exposed to some form of safety-related litigation over the past decade. The risk of adverse events from some on-market drugs is serious, and the use of prescription medications in the U.S. is increasing.
What is required – and often missing – in the examination of drug safety claims is a comprehensive understanding of the drug in question: not only the potential risks but also the potential widespread benefits of the drug, as well as its evolution from lab to market.
Epidemiologists and biostatisticians use a variety of analytical tools to assess claims related to drug safety, applying their knowledge of the relevant scientific context to help counsel address issues of causality, commonality, and potential damages.
These methods, honed over years of experience examining health outcomes, have helped our health care consultants create successful results for clients.
— Martha S. Samuelson, President and CEO